

IntelGenx Technologies Corp.  
Form 8-K  
April 03, 2017

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**April 3, 2017**  
Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**  
(Exact Name of Registrant as Specified in its Charter)

<b><u>Delaware</u></b> (State or other jurisdiction of incorporation)	<b><u>000-31187</u></b> (Commission File Number)	<b><u>870638336</u></b> (IRS Employer Identification No.)
---	--	---

<b><u>6420 Abrams, Ville St- Laurent, Quebec, Canada</u></b> (Address of principal executive offices)	<b><u>H4S 1Y2</u></b> (Zip Code)
--	-------------------------------------

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  - Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01 Other Events - News Release**

**IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet**

Exhibit Description

99.1 Press Release

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: April 3, 2017 By:

*/s/ Horst G. Zerbe*

-----

Horst G. Zerbe

President and Chief Executive Officer